
Opinion|Videos|August 5, 2024
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
A panel of experts discuss combination regimens with BTK inhibitors.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
3
Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates
4
Radiotherapy Plus Chemo Benefits Certain Patients With DLBCL
5














































